GLP-1 Peptide 10MG

Description

DESCRIPTION

Semaglutide is a long-acting GLP-1 receptor agonist studied in research models for its receptor binding profile, signaling activity, and stability characteristics. It is among the most extensively characterized incretin research peptides in the published literature.

RESEARCH AREAS

• GLP-1 receptor activation — studied in receptor binding and cAMP signaling assays.
• Pancreatic beta-cell models — investigated for receptor-mediated pathway activation in cell culture.
• Half-life characterization — published research describes extended pharmacokinetic profile relative to native GLP-1.
• Comparative receptor pharmacology — characterized alongside other GLP-1 receptor research compounds.

WHAT RESEARCHERS LOOK AT

• Mechanism: GLP-1 receptor agonism and downstream signaling.
• Receptor binding kinetics and selectivity.
• Stability and structural modifications relative to native GLP-1.
• Use as a reference compound in incretin receptor research.

QUICK SPECS

• Form: Lyophilized peptide
• Net per vial: 10 mg
• Purity: ≥99% (HPLC)
• Identity: MS-verified (per COA)
• Storage: 2–8 °C, protect from light

IDENTITY BASICS

• Type: GLP-1 receptor agonist
• Formula / M.W.: C187H291N45O59, ~4113.6 g/mol
• CAS: 910463-68-2

SELECTED RESEARCH

• PubChem entry — chemical identity:
  
  https://pubchem.ncbi.nlm.nih.gov/compound/56843331
  
• Receptor pharmacology and pathway:
  
  https://pubmed.ncbi.nlm.nih.gov/28916367/
  
• Pharmacokinetic profile (NEJM, 2021):
  
  https://pubmed.ncbi.nlm.nih.gov/33567185/
  
• Pharmacology and safety characterization (NEJM, 2016):
  
  https://pubmed.ncbi.nlm.nih.gov/27633186/
  

⚠️ DISCLAIMER

• This product is intended for laboratory research use only.

• Not for human or veterinary use.

• Not approved for diagnostic, therapeutic, or medical applications.

• Handle using appropriate laboratory safety procedures and personal protective equipment.